Total Payments
$13,800
2024 Payments
$1,910
Companies
49
Transactions
821
Medicare Patients
7,724
Medicare Billing
$404,616
Payment Breakdown by Category
Food & Beverage$13,199 (95.6%)
Education$601.18 (4.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,199 | 808 | 95.6% |
| Education | $601.18 | 13 | 4.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,883 | 118 | $0 (2024) |
| ABBVIE INC. | $1,177 | 70 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,125 | 63 | $0 (2024) |
| Novo Nordisk Inc | $1,081 | 66 | $0 (2024) |
| Lilly USA, LLC | $1,060 | 65 | $0 (2024) |
| Astellas Pharma US Inc | $961.91 | 40 | $0 (2024) |
| PFIZER INC. | $841.11 | 48 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $760.45 | 48 | $0 (2024) |
| Amgen Inc. | $469.56 | 26 | $0 (2024) |
| Allergan, Inc. | $449.87 | 36 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,910 | 103 | ABBVIE INC. ($308.85) |
| 2023 | $2,162 | 116 | GlaxoSmithKline, LLC. ($406.34) |
| 2022 | $2,149 | 124 | GlaxoSmithKline, LLC. ($472.89) |
| 2021 | $2,134 | 129 | Lilly USA, LLC ($326.32) |
| 2020 | $1,473 | 90 | Novo Nordisk Inc ($204.23) |
| 2019 | $1,421 | 84 | Astellas Pharma US Inc ($263.18) |
| 2018 | $1,581 | 109 | AstraZeneca Pharmaceuticals LP ($258.96) |
| 2017 | $970.95 | 66 | Novo Nordisk Inc ($142.25) |
All Payment Transactions
821 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: RESPIRATORY | ||||||
| 11/26/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: PSYCHIATRY | ||||||
| 11/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: PAIN | ||||||
| 11/07/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Oncology | ||||||
| 11/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.25 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $22.49 | General |
| Category: Biological | ||||||
| 10/23/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: UROLOGY | ||||||
| 10/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Cranial Technologies, Inc | Doc Band (Device) | Food and Beverage | Cash or cash equivalent | $19.56 | General |
| Category: Cranial Orthotic | ||||||
| 10/16/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Inflammation | ||||||
| 10/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: RESPIRATORY | ||||||
| 10/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: PAIN | ||||||
| 10/09/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Diabetes | ||||||
| 09/25/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/24/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: UROLOGY | ||||||
| 09/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: RESPIRATORY | ||||||
| 09/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: PAIN | ||||||
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,019 | 2,270 | $163,231 | $48,258 |
| 2022 | 30 | 1,624 | 2,833 | $207,429 | $72,935 |
| 2021 | 33 | 2,686 | 4,164 | $255,774 | $144,348 |
| 2020 | 40 | 2,395 | 3,891 | $287,034 | $139,075 |
Total Patients
7,724
Total Services
13,158
Medicare Billing
$404,616
Procedure Codes
123
All Medicare Procedures & Services
123 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 142 | 350 | $54,250 | $14,147 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 164 | 342 | $39,664 | $9,672 | 24.4% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 49 | 61 | $12,200 | $8,247 | 67.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 139 | 139 | $20,850 | $6,708 | 32.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 89 | 264 | $9,240 | $2,305 | 24.9% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 77 | 158 | $4,740 | $1,485 | 31.3% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 16 | 18 | $5,958 | $1,405 | 23.6% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 45 | 54 | $1,350 | $826.20 | 61.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 15 | 17 | $1,530 | $655.52 | 42.8% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 51 | 127 | $1,270 | $555.41 | 43.7% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 11 | 18 | $1,350 | $516.80 | 38.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 65 | 110 | $1,100 | $368.28 | 33.5% |
| J2010 | Injection, lincomycin hcl, up to 300 mg | Office | 2023 | 15 | 64 | $1,280 | $358.00 | 28.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 11 | 11 | $990.00 | $356.32 | 36.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 18 | 20 | $1,200 | $182.07 | 15.2% |
| 92250 | Photography of the retina | Office | 2023 | 11 | 11 | $1,199 | $163.74 | 13.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 54 | 300 | $3,000 | $103.53 | 3.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 12 | 12 | $120.00 | $100.80 | 84.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 18 | 88 | $880.00 | $64.94 | 7.4% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 17 | 106 | $1,060 | $37.50 | 3.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 157 | 391 | $60,605 | $16,153 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 191 | 415 | $43,160 | $11,348 | 26.3% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2022 | 44 | 57 | $11,400 | $8,003 | 70.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 105 | 109 | $9,810 | $7,313 | 74.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 156 | 156 | $23,400 | $6,848 | 29.3% |
About Dr. Gary Birdsall, M.D
Dr. Gary Birdsall, M.D is a Family Medicine healthcare provider based in Cut Off, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649213596.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Birdsall, M.D has received a total of $13,800 in payments from pharmaceutical and medical device companies, with $1,910 received in 2024. These payments were reported across 821 transactions from 49 companies. The most common payment nature is "Food and Beverage" ($13,199).
As a Medicare-enrolled provider, Birdsall has provided services to 7,724 Medicare beneficiaries, totaling 13,158 services with total Medicare billing of $404,616. Data is available for 4 years (2020–2023), covering 123 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Cut Off, LA
- Active Since 06/14/2006
- Last Updated 03/27/2014
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1649213596
Products in Payments
- TRELEGY ELLIPTA (Drug) $1,463
- VRAYLAR (Drug) $911.15
- FARXIGA (Drug) $755.51
- Ozempic (Drug) $591.75
- NURTEC ODT (Drug) $568.14
- JARDIANCE (Drug) $535.41
- CAPLYTA (Drug) $431.88
- UBRELVY (Drug) $427.64
- ELIQUIS (Drug) $394.46
- TRULICITY (Drug) $385.50
- EMGALITY (Drug) $305.69
- XARELTO (Drug) $291.01
- MYRBETRIQ (Drug) $288.91
- MOUNJARO (Drug) $254.18
- Aimovig (Biological) $228.85
- STIOLTO RESPIMAT (Drug) $211.67
- ENTRESTO (Drug) $203.88
- Victoza (Drug) $180.71
- Rybelsus (Drug) $169.09
- QULIPTA (Drug) $161.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.